Mapp Biopharmaceutical
San Diego · Founded 2003
About Mapp Biopharmaceutical
Mapp Biopharmaceutical was created to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. The company has been developing an Ebola therapy for more than a decade and has been working with the United States and Canadian governments to develop this therapy. Mapp Biopharmaceutical was founded in 2003 by Kevin Whaley and Larry Zeitlin. It is headquartered in San Diego, C.A.
Company Facts
- Founded: 2003
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $16.5M
- Last round: Grant (Jun 2019)
- Website: mappbio.com
- Phone: (858) 625-0335
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/mapp-biopharmaceutical-130910 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.